Company profile for XPhyto

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

XPhyto is a biotechnology and next-generation cannabis company focused on formulation, clinical validation, and European imports, distribution and sales. XPhyto’s 100% owned subsidiary, Vektor Pharma TF GmbH, a German narcotics manufacturer, importer and researcher has expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips. Vekto...
XPhyto is a biotechnology and next-generation cannabis company focused on formulation, clinical validation, and European imports, distribution and sales. XPhyto’s 100% owned subsidiary, Vektor Pharma TF GmbH, a German narcotics manufacturer, importer and researcher has expertise in the design, testing and manufacture of thin film drug delivery systems, particularly transdermal patches and sub-lingual (oral) strips. Vektor also holds a number of narcotics licences issued by the German Federal Institute for Drugs and Medical Devices (BfArM), including import and manufacturing permits, as well as EU GMP lab certification.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
Suite 1500 – 1055 W Georgia Street / Vancouver, BC V6E 4N7 / Canada
Telephone
Telephone
+1-780-818-6422
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accesswire.com/720788/XPhyto-Reports-Excellent-Rotigotine-In-VitroEx-Vivo-Results-for-Parkinsons-Disease-Treatment

ACCESSWIRE
18 Oct 2022

https://www.biospace.com/article/releases/xphyto-completes-rotigotine-transdermal-patch-optimization-and-comparative-skin-absorption-study/

BIOSPACE
11 Oct 2022

https://www.accesswire.com/718906/XPhyto-Signs-Letter-of-Intent-for-US-Manufacturing-and-Strategic-Business-Opportunities

ACCESSWIRE
04 Oct 2022

https://www.accesswire.com/716679/XPhyto-Files-Patent-Application-for-Library-of-Novel-Psychedelic-Compounds

ACCESSWIRE
20 Sep 2022

https://www.accesswire.com/714618/XPhyto-Closes-Final-Tranche-of-Fully-Subscribed-Financing

ACCESSWIRE
02 Sep 2022

https://www.accesswire.com/714218/XPhyto-Closes-Second-Tranche-of-Financing

ACCESSWIRE
31 Aug 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty